|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
Chains C, L:
E.C.3.4.21.22
- coagulation factor IXa.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Hydrolyzes one Arg-|-Ile bond in factor X to form factor Xa.
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
92:9796-9800
(1995)
|
|
PubMed id:
|
|
|
|
|
| |
|
X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B.
|
|
H.Brandstetter,
M.Bauer,
R.Huber,
P.Lollar,
W.Bode.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Hereditary deficiency of factor IXa (fIXa), a key enzyme in blood coagulation,
causes hemophilia B, a severe X chromosome-linked bleeding disorder afflicting 1
in 30,000 males; clinical studies have identified nearly 500 deleterious
variants. The x-ray structure of porcine fIXa described here shows the atomic
origins of the disease, while the spatial distribution of mutation sites
suggests a structural model for factor X activation by phospholipid-bound fIXa
and cofactor VIIIa. The 3.0-A-resolution diffraction data clearly show the
structures of the serine proteinase module and the two preceding epidermal
growth factor (EGF)-like modules; the N-terminal Gla module is partially
disordered. The catalytic module, with covalent inhibitor D-Phe-1I-Pro-2I-Arg-3I
chloromethyl ketone, most closely resembles fXa but differs significantly at
several positions. Particularly noteworthy is the strained conformation of
Glu-388, a residue strictly conserved in known fIXa sequences but conserved as
Gly among other trypsin-like serine proteinases. Flexibility apparent in
electron density together with modeling studies suggests that this may cause
incomplete active site formation, even after zymogen, and hence the low
catalytic activity of fIXa. The principal axes of the oblong EGF-like domains
define an angle of 110 degrees, stabilized by a strictly conserved and
fIX-specific interdomain salt bridge. The disorder of the Gla module, whose
hydrophobic helix is apparent in electron density, can be attributed to the
absence of calcium in the crystals; we have modeled the Gla module in its
calcium form by using prothrombin fragment 1. The arched module arrangement
agrees with fluorescence energy transfer experiments. Most hemophilic mutation
sites of surface fIX residues occur on the concave surface of the bent molecule
and suggest a plausible model for the membrane-bound ternary fIXa-FVIIIa-fX
complex structure: fIXa and an equivalently arranged fX arch across an
underlying fVIIIa subdomain from opposite sides; the stabilizing fVIIIa
interactions force the catalytic modules together, completing fIXa active site
formation and catalytic enhancement.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
D.Gaso-Sokac,
S.Kovac,
J.Clifton,
and
D.Josic
(2011).
Therapeutic plasma proteins - application of proteomics in process optimization, validation, and analysis of the final product.
|
| |
Electrophoresis,
32,
1104-1117.
|
 |
|
|
|
|
 |
C.N.Lin,
C.Y.Kao,
C.H.Miao,
N.Hamaguchi,
H.L.Wu,
G.Y.Shi,
Y.L.Liu,
K.A.High,
and
S.W.Lin
(2010).
Generation of a novel factor IX with augmented clotting activities in vitro and in vivo.
|
| |
J Thromb Haemost,
8,
1773-1783.
|
 |
|
|
|
|
 |
D.J.Johnson,
J.Langdown,
and
J.A.Huntington
(2010).
Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex.
|
| |
Proc Natl Acad Sci U S A,
107,
645-650.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
R.Hartmann,
M.Dockal,
W.Kammlander,
E.Panholzer,
G.A.Nicolaes,
C.Fiedler,
J.Rosing,
and
F.Scheiflinger
(2009).
Factor IX mutants with enhanced catalytic activity.
|
| |
J Thromb Haemost,
7,
1656-1662.
|
 |
|
|
|
|
 |
T.Zögg,
and
H.Brandstetter
(2009).
Activation mechanisms of coagulation factor IX.
|
| |
Biol Chem,
390,
391-400.
|
 |
|
|
|
|
 |
T.Zögg,
and
H.Brandstetter
(2009).
Structural basis of the cofactor- and substrate-assisted activation of human coagulation factor IXa.
|
| |
Structure,
17,
1669-1678.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Z.Wei,
Y.Yan,
R.W.Carrell,
and
A.Zhou
(2009).
Crystal structure of protein Z-dependent inhibitor complex shows how protein Z functions as a cofactor in the membrane inhibition of factor X.
|
| |
Blood,
114,
3662-3667.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Venceslá,
M.A.Corral-Rodríguez,
M.Baena,
M.Cornet,
M.Domènech,
M.Baiget,
P.Fuentes-Prior,
and
E.F.Tizzano
(2008).
Identification of 31 novel mutations in the F8 gene in Spanish hemophilia A patients: structural analysis of 20 missense mutations suggests new intermolecular binding sites.
|
| |
Blood,
111,
3468-3478.
|
 |
|
|
|
|
 |
J.C.Ngo,
M.Huang,
D.A.Roth,
B.C.Furie,
and
B.Furie
(2008).
Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex.
|
| |
Structure,
16,
597-606.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
L.Autin,
M.Steen,
B.Dahlbäck,
and
B.O.Villoutreix
(2006).
Proposed structural models of the prothrombinase (FXa-FVa) complex.
|
| |
Proteins,
63,
440-450.
|
 |
|
|
|
|
 |
M.P.Bicocchi,
M.Pasino,
C.Rosano,
A.C.Molinari,
E.Della Valle,
T.Lanza,
F.Bottini,
and
M.Acquila
(2006).
Insight into molecular changes of the FIX protein in a series of Italian patients with haemophilia B.
|
| |
Haemophilia,
12,
263-270.
|
 |
|
|
|
|
 |
B.A.Lwaleed,
R.Greenfield,
E.Royle,
B.Birch,
and
A.J.Cooper
(2005).
Seminal Factor VIII and von Willebrand Factor: a possible role of the conventional clotting system in human semen?
|
| |
Int J Androl,
28,
31-38.
|
 |
|
|
|
|
 |
L.Autin,
M.A.Miteva,
W.H.Lee,
K.Mertens,
K.P.Radtke,
and
B.O.Villoutreix
(2005).
Molecular models of the procoagulant factor VIIIa-factor IXa complex.
|
| |
J Thromb Haemost,
3,
2044-2056.
|
 |
|
|
|
|
 |
P.J.Fay,
and
P.V.Jenkins
(2005).
Mutating factor VIII: lessons from structure to function.
|
| |
Blood Rev,
19,
15-27.
|
 |
|
|
|
|
 |
W.Bode
(2005).
The structure of thrombin, a chameleon-like proteinase.
|
| |
J Thromb Haemost,
3,
2379-2388.
|
 |
|
|
|
|
 |
H.C.Whinna,
E.B.Lesesky,
D.M.Monroe,
K.A.High,
P.J.Larson,
and
F.C.Church
(2004).
Role of the gamma-carboxyglutamic acid domain of activated factor X in the presence of calcium during inhibition by antithrombin-heparin.
|
| |
J Thromb Haemost,
2,
1127-1134.
|
 |
|
|
|
|
 |
P.J.Fay
(2004).
Activation of factor VIII and mechanisms of cofactor action.
|
| |
Blood Rev,
18,
1.
|
 |
|
|
|
|
 |
T.Morita
(2004).
Use of snake venom inhibitors in studies of the function and tertiary structure of coagulation factors.
|
| |
Int J Hematol,
79,
123-129.
|
 |
|
|
|
|
 |
B.R.Lentz
(2003).
Exposure of platelet membrane phosphatidylserine regulates blood coagulation.
|
| |
Prog Lipid Res,
42,
423-438.
|
 |
|
|
|
|
 |
K.E.Knobe,
K.E.Persson,
E.Sjörin,
B.O.Villoutreix,
J.Stenflo,
and
R.C.Ljung
(2003).
Functional analysis of the EGF-like domain mutations Pro55Ser and Pro55Leu, which cause mild hemophilia B.
|
| |
J Thromb Haemost,
1,
782-790.
|
 |
|
|
|
|
 |
M.J.Wood,
L.A.Becvar,
J.H.Prieto,
G.Melacini,
and
E.A.Komives
(2003).
NMR structures reveal how oxidation inactivates thrombomodulin.
|
| |
Biochemistry,
42,
11932-11942.
|
 |
|
|
|
|
 |
R.Majumder,
J.Wang,
and
B.R.Lentz
(2003).
Effects of water soluble phosphotidylserine on bovine factor Xa: functional and structural changes plus dimerization.
|
| |
Biophys J,
84,
1238-1251.
|
 |
|
|
|
|
 |
S.S.Ahmad,
F.S.London,
and
P.N.Walsh
(2003).
The assembly of the factor X-activating complex on activated human platelets.
|
| |
J Thromb Haemost,
1,
48-59.
|
 |
|
|
|
|
 |
D.J.Bowen
(2002).
Haemophilia A and haemophilia B: molecular insights.
|
| |
Mol Pathol,
55,
1.
|
 |
|
|
|
|
 |
D.J.Bowen
(2002).
Haemophilia A and haemophilia B: molecular insights.
|
| |
Mol Pathol,
55,
127-144.
|
 |
|
|
|
|
 |
K.High
(2002).
AAV-mediated gene transfer for hemophilia.
|
| |
Genet Med,
4,
56S-61S.
|
 |
|
|
|
|
 |
H.Mizuno,
Z.Fujimoto,
H.Atoda,
and
T.Morita
(2001).
Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X.
|
| |
Proc Natl Acad Sci U S A,
98,
7230-7234.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.Gaboriaud,
V.Rossi,
I.Bally,
G.J.Arlaud,
and
J.C.Fontecilla-Camps
(2000).
Crystal structure of the catalytic domain of human complement c1s: a serine protease with a handle.
|
| |
EMBO J,
19,
1755-1765.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.A.Kolkman,
and
K.Mertens
(2000).
Insertion loop 256-268 in coagulation factor IX restricts enzymatic activity in the absence but not in the presence of factor VIII.
|
| |
Biochemistry,
39,
7398-7405.
|
 |
|
|
|
|
 |
L.Perera,
C.Foley,
T.A.Darden,
D.Stafford,
T.Mather,
C.T.Esmon,
and
L.G.Pedersen
(2000).
Modeling zymogen protein C.
|
| |
Biophys J,
79,
2925-2943.
|
 |
|
|
|
|
 |
A.C.Pike,
A.M.Brzozowski,
S.M.Roberts,
O.H.Olsen,
and
E.Persson
(1999).
Structure of human factor VIIa and its implications for the triggering of blood coagulation.
|
| |
Proc Natl Acad Sci U S A,
96,
8925-8930.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
H.Czapinska,
and
J.Otlewski
(1999).
Structural and energetic determinants of the S1-site specificity in serine proteases.
|
| |
Eur J Biochem,
260,
571-595.
|
 |
|
|
|
|
 |
J.Jin,
J.Chang,
J.Y.Chang,
R.F.Kelley,
D.W.Stafford,
and
D.L.Straight
(1999).
Factor VIIa's first epidermal growth factor-like domain's role in catalytic activity.
|
| |
Biochemistry,
38,
1185-1192.
|
 |
|
|
|
|
 |
K.E.Knobe,
A.Berntsdotter,
L.Shen,
J.Morser,
B.Dahlbäck,
and
B.O.Villoutreix
(1999).
Probing the activation of protein C by the thrombin-thrombomodulin complex using structural analysis, site-directed mutagenesis, and computer modeling.
|
| |
Proteins,
35,
218-234.
|
 |
|
|
|
|
 |
K.P.Hopfner,
A.Lang,
A.Karcher,
K.Sichler,
E.Kopetzki,
H.Brandstetter,
R.Huber,
W.Bode,
and
R.A.Engh
(1999).
Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding.
|
| |
Structure,
7,
989-996.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Y.Wong,
J.A.Gurr,
and
P.N.Walsh
(1999).
The second epidermal growth factor-like domain of human factor IXa mediates factor IXa binding to platelets and assembly of the factor X activating complex.
|
| |
Biochemistry,
38,
8948-8960.
|
 |
|
|
|
|
 |
R.J.Kaufman
(1999).
Advances toward gene therapy for hemophilia at the millennium.
|
| |
Hum Gene Ther,
10,
2091-2107.
|
 |
|
|
|
|
 |
A.Muranyi,
B.E.Finn,
G.P.Gippert,
S.Forsén,
J.Stenflo,
and
T.Drakenberg
(1998).
Solution structure of the N-terminal EGF-like domain from human factor VII.
|
| |
Biochemistry,
37,
10605-10615.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.W.Ashton,
M.K.Boehm,
D.J.Johnson,
G.Kemball-Cook,
and
S.J.Perkins
(1998).
The solution structure of human coagulation factor VIIa in its complex with tissue factor is similar to free factor VIIa: a study of a heterodimeric receptor-ligand complex by X-ray and neutron scattering and computational modeling.
|
| |
Biochemistry,
37,
8208-8217.
|
 |
|
|
|
|
 |
B.Bersch,
J.F.Hernandez,
D.Marion,
and
G.J.Arlaud
(1998).
Solution structure of the epidermal growth factor (EGF)-like module of human complement protease C1r, an atypical member of the EGF family.
|
| |
Biochemistry,
37,
1204-1214.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
D.Chamberlain,
C.G.Ullman,
and
S.J.Perkins
(1998).
Possible arrangement of the five domains in human complement factor I as determined by a combination of X-ray and neutron scattering and homology modeling.
|
| |
Biochemistry,
37,
13918-13929.
|
 |
|
|
|
|
 |
D.Lillicrap
(1998).
The molecular basis of haemophilia B.
|
| |
Haemophilia,
4,
350-357.
|
 |
|
|
|
|
 |
F.Fraternali,
Q.T.Do,
B.T.Doan,
R.A.Atkinson,
P.Palmas,
V.Sklenar,
P.Safar,
P.Wildgoose,
P.Strop,
and
V.Saudek
(1998).
Mapping the active site of factor Xa by selective inhibitors: an NMR and MD study.
|
| |
Proteins,
30,
264-274.
|
 |
|
|
|
|
 |
F.Giannelli,
P.M.Green,
S.S.Sommer,
M.Poon,
M.Ludwig,
R.Schwaab,
P.H.Reitsma,
M.Goossens,
A.Yoshioka,
M.S.Figueiredo,
and
G.G.Brownlee
(1998).
Haemophilia B: database of point mutations and short additions and deletions--eighth edition.
|
| |
Nucleic Acids Res,
26,
265-268.
|
 |
|
|
|
|
 |
G.Kemball-Cook,
E.G.Tuddenham,
and
A.I.Wacey
(1998).
The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4.
|
| |
Nucleic Acids Res,
26,
216-219.
|
 |
|
|
|
|
 |
K.Kamata,
H.Kawamoto,
T.Honma,
T.Iwama,
and
S.H.Kim
(1998).
Structural basis for chemical inhibition of human blood coagulation factor Xa.
|
| |
Proc Natl Acad Sci U S A,
95,
6630-6635.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
K.P.Hopfner,
E.Kopetzki,
G.B.Kresse,
W.Bode,
R.Huber,
and
R.A.Engh
(1998).
New enzyme lineages by subdomain shuffling.
|
| |
Proc Natl Acad Sci U S A,
95,
9813-9818.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.M.Hackeng,
P.E.Dawson,
S.B.Kent,
and
J.H.Griffin
(1998).
Chemical synthesis of human protein S thrombin-sensitive module and first epidermal growth factor module.
|
| |
Biopolymers,
46,
53-63.
|
 |
|
|
|
|
 |
F.Giannelli,
P.M.Green,
S.S.Sommer,
M.C.Poon,
M.Ludwig,
R.Schwaab,
P.H.Reitsma,
M.Goossens,
A.Yoshioka,
M.S.Figueiredo,
and
G.G.Brownlee
(1997).
Haemophilia B: database of point mutations and short additions and deletions, 7th edition.
|
| |
Nucleic Acids Res,
25,
133-135.
|
 |
|
|
|
|
 |
J.Y.Chang,
D.M.Monroe,
D.W.Stafford,
K.M.Brinkhous,
and
H.R.Roberts
(1997).
Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B.
|
| |
J Clin Invest,
100,
886-892.
|
 |
|
|
|
|
 |
K.P.Hopfner,
H.Brandstetter,
A.Karcher,
E.Kopetzki,
R.Huber,
R.A.Engh,
and
W.Bode
(1997).
Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants.
|
| |
EMBO J,
16,
6626-6635.
|
 |
|
|
|
|
 |
M.Renatus,
M.T.Stubbs,
R.Huber,
P.Bringmann,
P.Donner,
W.D.Schleuning,
and
W.Bode
(1997).
Catalytic domain structure of vampire bat plasminogen activator: a molecular paradigm for proteolysis without activation cleavage.
|
| |
Biochemistry,
36,
13483-13493.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Renatus,
R.A.Engh,
M.T.Stubbs,
R.Huber,
S.Fischer,
U.Kohnert,
and
W.Bode
(1997).
Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA.
|
| |
EMBO J,
16,
4797-4805.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Kurachi,
D.P.Pantazatos,
and
K.Kurachi
(1997).
The carboxyl-terminal region of factor IX is essential for its secretion.
|
| |
Biochemistry,
36,
4337-4344.
|
 |
|
|
|
|
 |
A.K.Downing,
V.Knott,
J.M.Werner,
C.M.Cardy,
I.D.Campbell,
and
P.A.Handford
(1996).
Solution structure of a pair of calcium-binding epidermal growth factor-like domains: implications for the Marfan syndrome and other genetic disorders.
|
| |
Cell,
85,
597-605.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.D.Dickinson,
C.R.Kelly,
and
W.Ruf
(1996).
Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa.
|
| |
Proc Natl Acad Sci U S A,
93,
14379-14384.
|
 |
|
|
|
|
 |
D.Kirchhofer,
and
Y.Nemerson
(1996).
Initiation of blood coagulation: the tissue factor/factor VIIa complex.
|
| |
Curr Opin Biotechnol,
7,
386-391.
|
 |
|
|
|
|
 |
M.Sunnerhagen,
G.A.Olah,
J.Stenflo,
S.Forsén,
T.Drakenberg,
and
J.Trewhella
(1996).
The relative orientation of Gla and EGF domains in coagulation factor X is altered by Ca2+ binding to the first EGF domain. A combined NMR-small angle X-ray scattering study.
|
| |
Biochemistry,
35,
11547-11559.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
P.Hof,
I.Mayr,
R.Huber,
E.Korzus,
J.Potempa,
J.Travis,
J.C.Powers,
and
W.Bode
(1996).
The 1.8 A crystal structure of human cathepsin G in complex with Suc-Val-Pro-PheP-(OPh)2: a Janus-faced proteinase with two opposite specificities.
|
| |
EMBO J,
15,
5481-5491.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
P.O.Freskgård,
O.H.Olsen,
and
E.Persson
(1996).
Structural changes in factor VIIa induced by Ca2+ and tissue factor studied using circular dichroism spectroscopy.
|
| |
Protein Sci,
5,
1531-1540.
|
 |
|
|
|
|
 |
R.A.Engh,
H.Brandstetter,
G.Sucher,
A.Eichinger,
U.Baumann,
W.Bode,
R.Huber,
T.Poll,
R.Rudolph,
and
W.von der Saal
(1996).
Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug design.
|
| |
Structure,
4,
1353-1362.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
T.Mather,
V.Oganessyan,
P.Hof,
R.Huber,
S.Foundling,
C.Esmon,
and
W.Bode
(1996).
The 2.8 A crystal structure of Gla-domainless activated protein C.
|
| |
EMBO J,
15,
6822-6831.
|
 |
|
PDB code:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |